19 citations
,
February 1998 in “Cellular Immunology” Hair growth phase in mice weakens certain immune responses.
20 citations
,
September 2003 in “Journal of Investigative Dermatology” Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.
140 citations
,
March 2013 in “The journal of immunology/The Journal of immunology” Memory regulatory T cells need IL-7, not IL-2, to stay in peripheral tissues.
May 2024 in “Frontiers in Immunology” Type-2 immunity may influence skin diseases and could be targeted for treatment.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
ILC1-like cells may contribute to hair loss in alopecia areata and could be new treatment targets.
15 citations
,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
April 2018 in “Journal of Investigative Dermatology” Blocking a specific immune cell signal can trigger hair growth.
January 2026 in “International Journal of Molecular Sciences” Hedgehog pathway inhibitors could be effective in treating melanoma.
130 citations
,
November 2017 in “Frontiers in Immunology” The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.
32 citations
,
June 2012 in “PLoS ONE” Blocking IL-8 can reduce skin rashes from cancer treatment.
69 citations
,
February 2008 in “The American journal of pathology” Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
1 citations
,
July 2025 in “Journal of Investigative Dermatology” IL-27 may help prevent hair loss by creating immune-suppressing cells.
20 citations
,
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” IFN-γ and IL-2 are important for T cell activation in hair loss in mice.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
July 2022 in “Journal of Investigative Dermatology”
8 citations
,
February 2015 in “Cellular immunology” Deleting Snai2 and Snai3 causes fatal autoimmunity.
1066 citations
,
March 2010 in “Nature Reviews Molecular Cell Biology” MicroRNAs are crucial in controlling cell signaling, affecting cancer and tissue regeneration.
16 citations
,
January 2016 in “Journal of Investigative Dermatology” Mice without the IL-6 gene had more hair growth after injury due to higher activity of a related protein, Stat3.
10 citations
,
November 2023 in “Science Immunology” Super-enhancers control CD25 expression in specific cell types, affecting immune function.
5 citations
,
June 2022 in “Frontiers in immunology” Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.
32 citations
,
August 2016 in “Science Signaling” Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.
23 citations
,
January 2016 in “Frontiers in immunology” Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.
48 citations
,
January 2024 in “Immune Network” IL-15 is key for T cell function and could help improve treatments for immune-related diseases.
60 citations
,
October 2020 in “Nature Communications” AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.
18 citations
,
January 2013 in “Journal of Investigative Dermatology” WIF1 helps keep skin stem cells inactive to prevent excessive cell growth.
53 citations
,
July 2009 in “Cancer Research” Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
1 citations
,
November 2024 in “Blood” PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.
November 2022 in “Journal of the Endocrine Society” Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.